Table 2.
Stereotactic body radiation therapy for locally advanced pancreatic cancer.
| Study | Patients, n | SBRT dose (in Gy) | Grade 3+ GI toxicities (unless other wise specified) | Local control at 1 year | Median OS (months) | Median follow-up (months) |
|---|---|---|---|---|---|---|
| Koong et al.16 | 15 | 15, 20, or 25 Gy × 1 | 0 | 100% | 11 | 5 |
| Koong et al.17 | 19 | 45 Gy IMRT followed by 25 Gy × 1 boost | 2 (12.5%) | 94% | 8.3 | 6 |
| Hoyer et al.18 | 22 | 15Gy × 3 | 79% acute grade 2+ | 57% | 5.4 | Not available |
| Schellenberg et al.19 | 16 | 25 Gy × 1 after induction gemcitabine + post-SBRT gemcitabine | 1 (6%) acute 2 (13%) late |
100% | 11.4 | 9.1 for all patients; 22.3 for living patients |
| Schellenberg et al.20 | 20 | 25 Gy × 1 after induction gemcitabine + post-SBRT gemcitabine | 0 acute 1 (5%) late |
94% | 11.8 | 4.3 |
| Herman et al.21 | 49 | 6.6 Gy × 5 after induction gemcitabine | 1 (2%) acute 3 (6%) late |
78% | 13.9 | 13.9 |
| Mahadevan et al.24 | 36 | 8, 10, or 12 Gy × 3 followed by adjuvant gemcitabine | 5 (14%) | 78% | 14.3 | 24 |
| Mahadevan et al.25 | 39 | 8–12 Gy × 3 after induction gemcitabine | 0 acute 3 (9%) late |
85% | 20 | 21 |
| Gurka et al.26 | 10 | 5 Gy × 5 with concurrent gemcitabine | 0 | 40% | 12.2 | Not available |
| Polistina et al.28 | 23 | 10 Gy × 3 with induction and concurrent gemcitabine, ± surgery, ± maintenance chemotherapy | 0 | 82.6% | 10.6 | 9 |